Cargando…

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study

BACKGROUND: Several disease-modifying drugs have shown promising effects on cognitive impairment in multiple sclerosis (MS). Alemtuzumab, a humanized monoclonal antibody, is effective in controlling disease activity, however, has not been evaluated for its effects on cognition in detail so far. OBJE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riepl, Ester, Pfeuffer, Steffen, Ruck, Tobias, Lohmann, Hubertus, Wiendl, Heinz, Meuth, Sven G., Johnen, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775967/ https://www.ncbi.nlm.nih.gov/pubmed/29387035 http://dx.doi.org/10.3389/fneur.2017.00730

Ejemplares similares

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
por: Möhn, Nora, et al.
Publicado: (2019)

Long-term efficacy of alemtuzumab in polymyositis
por: Ruck, Tobias, et al.
Publicado: (2015)

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2019)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment
por: Haas, Jürgen, et al.
Publicado: (2019)

ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential
por: Ruck, Tobias, et al.
Publicado: (2016)

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019)

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response
por: Bierhansl, Laura, et al.
Publicado: (2019)

Comment on “Alemtuzumab improves cognitive processing speed in active multiple sclerosis – a longitudinal observational study”
por: Asadollahzade, Elnaz, et al.
Publicado: (2022)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity
por: Ruck, Tobias, et al.
Publicado: (2022)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Can cognitive assessment really discriminate early stages of Alzheimer’s and behavioural variant frontotemporal dementia at initial clinical presentation?
por: Reul, Sophia, et al.
Publicado: (2017)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation
por: Rolfes, Leoni, et al.
Publicado: (2021)

DTI detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis()
por: Deppe, Michael, et al.
Publicado: (2013)

Apraxia profiles—A single cognitive marker to discriminate all variants of frontotemporal lobar degeneration and Alzheimer's disease
por: Johnen, Andreas, et al.
Publicado: (2018)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Case Report: Adult Still’s Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient
por: Krämer, Julia, et al.
Publicado: (2020)

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
por: Wiendl, Heinz, et al.
Publicado: (2015)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation
por: Loos, Julia, et al.
Publicado: (2020)

The Agony of Choice? Preserved Affective Decision Making in Early Multiple Sclerosis
por: Landmeyer, Nils C., et al.
Publicado: (2020)

Autoimmunity complicating SARS-CoV-2 infection in selective IgA-deficiency
por: Pfeuffer, Steffen, et al.
Publicado: (2020)

Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis
por: Deppe, Michael, et al.
Publicado: (2014)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function
por: Kleffner, Ilka, et al.
Publicado: (2017)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_njm2d9oepp69ppu6o68vvgfin2